IP Library Granted Patent US 6,911,461
Granted Patent B2
US 6,911,461 · App. 10/693,917 · Granted Jun 28, 2005

2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

Assignee: UCB, S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,911,461
App. No.
10/693,917
Granted
Jun 28, 2005
Kind
B2
Abstract

The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Claims (5)

1. (4R) and (4S) diastereoisomers of (2S)-2-[2-oxy-4-propylpyrrolidinyl]butanamide or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.

3. A method for treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse, stroke, myoclonus, essential tremor, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity, Parkinson's disease, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis, in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound according to claim 1 .

4. The method according to claim 3 , wherein the condition to be treated is epilepsy, neuropathic pain, bipolar disorder or migraine.

5. (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]butanamide or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Mar 18, 2020
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 052187/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2015
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 035112/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2008
From: UCB, S.A.
To: UCB PHARMA, S.A.
Reel/Frame 021773/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2007
From: UCB, S.A.
To: UCB PHARMA, S.A.
Reel/Frame 019047/0447 →
Priority Claims (1)
GB 0004297 · Feb 23, 2000 · national
Continuity (2)
Division 1020426600
Related Publication 20040116507A1 · Jun 17, 2004